INTENDIS INC. AND CORIA LABORATORIES ANNOUNCE INTRODUCTION OF FINACEA® Plus™

San Francisco, CA – March 9, 2009

Intendis Inc., and Coria Laboratories are announcing the launch of FINACEA® Plus™ at the 67th Annual Meeting of the American Academy of Dermatology. FINACEA® Plus™ is a convenient system that helps treat mild to moderate rosacea, as well as cleanse and moisturize the skin.

Dermatology healthcare professionals agree on the importance of adding effective skin care to the successful management of rosacea. The skin of the rosacea patient, especially when it is treated with topical medications, needs to be gently cleansed and moisturized. FINACEA® Plus™ can help these patients do that easily and effectively.

FINACEA® Plus™ packages together FINACEA®, the first FDA-approved prescription gel for treating the bumps, pimples and redness of mild to moderate rosacea, with 3 oz bottles of CeraVe® Moisturizing Lotion and CeraVe® Hydrating Cleanser. Putting these three components in one convenient package offers patients an easy way to help manage their symptoms and take good care of their skin. CeraVe® Hydrating Cleanser provides gentle, effective cleansing while it restores and enhances the skin barrier. CeraVe® Moisturizing Lotion is uniquely formulated to increase the skin’s ability to attract, hold and distribute moisture.

“We are very excited about FINACEA® Plus™ because in one package it puts skin care and treatment conveniently into the hands of the rosacea patient,” said Bernhard Schefter, President and CEO Intendis, Inc. “Our goal is to help make rosacea management easier for the patient by providing them with a comprehensive solution so that they can treat their condition successfully.”

Instructions that accompany FINACEA® Plus™ recommend that rosacea patients wash their skin with lukewarm water and CeraVe® Hydrating Cleanser. This should be followed by an application of FINACEA®. Finally, it recommends applying CeraVe® Moisturizing Lotion to the entire face.

The prescription for FINACEA® Plus™ offers patients a $10 coupon towards the prescription cost of FINACEA® and a $2 coupon toward the purchase of either CeraVe® Moisturizing Lotion or CeraVe® Hydrating Cleanser.

About Rosacea

Rosacea is a condition that affects approximately 14 million adults in the U.S. It affects primarily the face and is characterized by the appearance of inflammatory lesions (papules and pustules), erythema (skin redness) and telangiectasia (spider veins).

About FINACEA®

Finacea® is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

Finacea® is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. Finacea® is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety – Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexion, these patients should be monitored for early signs of hypopigmentation.

About Intendis

Intendis Inc. is an U.S. based affiliate of Intendis GmbH, a fully integrated pharmaceutical company based in Berlin, Germany. As part of the Bayer Group, Intendis is fully dedicated to Dermatology and focuses on the development and marketing of high quality, innovative topical therapies, targeted to treat skin disorders. Intendis’ objective is to become a leading partner in the field of dermatology. Find out more at www.intendis.com

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

• Download, 32 KB